Mycoplasma Testing Market Analysis

Global Mycoplasma Testing Market Overview

Mycoplasma Testing Market Size was valued at USD 0.38 Billion in 2023. The Global Mycoplasma Testing industry is projected to grow from USD 0.45 Billion in 2024 to USD 0.082 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.45% during the forecast period (2024 - 2032).

Mycoplasma testing is used to detect contamination in a biological sample. Increasing R&D costs and new product releases are projected to drive the market growth of the mycoplasma testing. 

The availability of alternative conventional methods will impede the market growth of the mycoplasma testing over the projection period. The market of mycoplasma testing is divided into three categories: product, technique, and application. The market is divided into three categories: kits and reagents, instruments, and services. In 2017, the kits and reagents category is predicted to account for the greatest proportion of the market.

Agathos Biologics has offered analytical testing services to life science researchers since April 2023. Agathos exclusively uses QIAcuity instruments and QIAGEN-developed assays. Moreover, Agathos has collaborated with QIAGEN to perform mycoplasma as well as recombinant adeno-associated viral vector (rAAV) assay testing and validation.

Thermo Fisher Scientific, Inc. launched the TrueMark STI Select Panel in February 2023. It is meant to detect the four most common STIs with only a single-panel application. The panel can be used to detect Chlamydia trachomatis and Mycoplasma genitalium by means of polymerase chain reaction.

As an example, SwiftDx brought to market a new mycoplasma detection kit in February 2023. The newly introduced SwiftDx Mycoplasma Detection Kit uses the Lateral Flow test for fast and easy detection of mycoplasma contaminants.

Merck KGaA spent over $427.3m (€399m) on its Life Science Business’s R&D facilities in December 2022. This investment will help companies develop new, innovative diagnostic technologies, including those that detect mycoplasmas, leading to more accurate, sensitive and affordable tests for these diseases, hence increasing its market penetration.

Abbott received approval from the United States Food and Drug Administration on Alinity m STI Assay in May 2022. The test can concurrently identify or differentiate four common STDs like MG (Mycoplasma genitalium).

Performer Availability Screening Service, Inc.(PASS) has partnered with Spankchain in April 2022 to launch an initiative that screens and treats Las Vegas performers who have Mycoplasma genitalium until one thousand performers are reached.

For instance, Fujifilm is investing approximately USD 76 million in Massachusetts in January 2021 for advanced research and development in cell and gene therapy, gene editing, immunotherapy as well as biotechnology.

In July 2020, Roche Diagnostics introduced Cobas 6800 which is an automatic system in India.

Mycoplasma testing is expected to expand due to rising R&D expenditures and the introduction of new products. However, competition from more established technologies will slow the mycoplasma testing market's expansion throughout the forecast period. With better healthcare infrastructure, more unmet healthcare requirements, and more mycoplasma contamination, emerging markets are likely to fuel the expansion of the mycoplasma testing market share. The testing of biologics and vaccines for mycoplasma contamination is also required by recommendations and rules published by regulatory organizations including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Because of this, mycoplasma testing has become more important in the biopharmaceutical sector.

The expansion of the mycoplasma testing market is being fueled by technical developments such as the creation of quicker and more accurate mycoplasma testing methods and devices. In addition, the demand for biologics and biosimilars is rising, which is fueling market expansion. Biologics and biosimilars are susceptible to mycoplasma infection during production, which poses hazards to product quality, effectiveness, and patient safety. Mycoplasma testing solutions are becoming increasingly important as the need for biologics and biosimilars develops, driving the industry forward. 

In April 2023: Agathos Biologics, a frontrunner in the biotech industry, said it will begin providing cutting-edge analytical testing to the life sciences. Their expert staff uses cutting-edge technology to provide unrivaled precision in nucleic acid measurement and cellular analysis, with a particular emphasis on high-content imaging and digital PCR. Agathos relied only on QIAcuity instruments and tests from QIAGEN, and the two companies worked together to validate mycoplasma and rAAV assays.

In December 2022: Pictor, a New Zealand (NZ) startup with offices in the US and India, announced a funding round to advance its Human Health and Animal Health product pipelines and expand into new markets in Australia/New Zealand, the US, and Europe. In light of the recent success of the PictArray SARS-CoV-2 IgG Antibody Test, distributed by Rako Science in New Zealand and major partners in the United States, this development comes as no surprise. To better manage dairy and beef herds in New Zealand and throughout the world, the firm will introduce its PictArray Mycoplasma bovis and Johne's disease tests in the second quarter of 2023.

Mycoplasma Testing Market Segment Insights

The mycoplasma testing market has been segmented into product, Technique, and application.

Mycoplasma Testing Product Insights

Based on product, market segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share segment of the market.

Mycoplasma Testing Technique Insights

Based on Technique, market segmented into DNA Stain, Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.

Mycoplasma Testing Application Insights

Based on application, market segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.

Mycoplasma Testing End User Insights

Based on end user, market segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others.

Mycoplasma Testing Regional Insights

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The mycoplasma testing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European market of mycoplasma testing has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The mycoplasma testing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market for mycoplasma testing in the Middle East & Africa has been segmented into the Middle East and Africa.

April 2023: Polymerase chain reaction (PCR) research use only test designed to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in one test; includes RNase P as a human internal control; released by Thermo Fisher Scientific in February 2023. Rather of having laboratories do separate tests for each of the four most prevalent STIs, this solution can do so on a single panel. Researchers will be able to detect these sexually transmitted pathogenic germs more quickly and accurately thanks to this panel, which will aid in the development of future testing protocols and therapies.

Mycoplasma Testing Market Top Key players

Some of the key players in the mycoplasma testing market are:

• Charles River Laboratories, 


• Inc., Merck KGaA, 


• Lonza Group Ltd, 


• Roche Diagnostics, 


• SGS S.A., 


• American Type Culture Collection, 


• Invivogen, 


• Wuxi Apptec, 


• Thermo Fisher Scientific Inc., 


• Promocell GmbH

Regional Market Summary

Geographically, the Americas is anticipated to dominate the mycoplasma testing market owing to a well-established player and increasing R&D expenses.

Europe is expected to hold the second largest position in the market of mycoplasma testing. The market growth in this region is attributed to the growth in pharmaceutical and medical devices industry.

The mycoplasma testing market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing adoption of these products.

The Middle East & Africa has the least share of the market.

Mycoplasma Testing Market Segmentation

Mycoplasma Testing Product Outlook

• Kits & Reagents


• Instruments


• Services

Mycoplasma Testing Technique Outlook

• DNA Stain


• Enzyme-based


• PCR


• ELISA


• Direct Assay


• Indirect Assay


• Others

Mycoplasma Testing Application Outlook

• Cell Line and Cell Therapy Testing


• Virus Testing


• Row Material Testing


• Lot Release Testing


• Others

Mycoplasma Testing End User Outlook

• Pharmaceutical and Biological Manufacturing


• Contract Research Organizations


• Cell Banks


• Others

Mycoplasma Testing Region Outlook

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • South America
  
  
  
  


• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • UK
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

The report for Mycoplasma Testing Market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.

Recent Development

Lonza Group Ltd (Lonza) is a corporation that provides contract manufacturing and development solutions. It provides commercial mammalian and microbial production, clinical development, and manufacturing services. It also provides active pharmaceutical components with high potential, cell and gene therapy capabilities, sophisticated intermediates, oral medication product development services, cell culture models, genome editing, endotoxin products, and research media and testing goods. Lonza offers health and well-being solutions, microbiological and hygiene management, composites, and material protection. The corporation has production and research and development centers throughout Asia, Europe, and the Americas. Lonza is based in Basel, Switzerland.

The American Type Culture Collection (ATCC) is an important medical research resource. It is the world's foremost storehouse of biological cultures. Through in-house initiatives and collaborative collaborations, the ATCC conducts research to improve the propagation, preservation, categorization, and characterization of cultures, as well as to generate new and improved culture products. The ATCC was founded in 1925 and is presently located in Manassas, Virginia.

Intended Audience

• Mycoplasma testing products Manufacturers and vendors


• Mycoplasma testing service providers


• Pharmaceutical and Biotech companies


• Contract research organization


• Various research and consulting firms